Clinical Trial Protocol

A randomized double-blind placebo controlled cross-over trial of sodium nitrate in patients with stable angina. Inorganic Nitrate in Angina Study (INAS)

Konstantin Schwarz1,2, Satnam Singh1, Satish Kumar Parasaruman1,3, Maggie Bruce1, Lee Shepstone3, Martin Feelisch4, Magdalena Minnion5, Shakil Ahmad5, John Horowitz1,6, Dana Dawson1, Michael Frenneaux1,3*

1School of Medicine & Dentistry, University of Aberdeen, Aberdeen, UK
2Worcestershire Royal Hospital, Worcester, UK
3Norwich Medical School, University of East Anglia, Bob Champion Research and Education Building James Watson Road, Norwich, NR4 7UQ, UK
4University of Southampton, Southampton, UK
5Aston Medical Research Institute, Aston Medical School, Aston University, Birmingham, B4 7ET, UK
6University of Adelaide, Adelaide, Australia

*m.frenneaux@uea.ac.uk

Abstract

In an aging western population a significant number of patients continue to suffer from angina once all revascularization and optimal medical treatment options are exhausted. Under experimental conditions oral supplementation with inorganic nitrate was shown to exhibit mild blood pressure lowering effect, and has also been shown to promote angiogenesis, improve endothelial dysfunction and mitochondrial efficiency in skeletal muscle. It is unknown whether similar changes occur in cardiac muscle. In the current study we investigate whether oral sodium nitrate treatment will improve myocardial ischaemia in patients with stable angina.
Background

In 2013 the British Heart Foundation reported that 2.3 million patients (3.5% of the population) were registered with the diagnosis of angina in the United Kingdom (1). Despite impressive advances in revascularization options and optimal medical treatment over the last two decades, a significant number of patients continue to suffer from limiting angina. With improving survival and active lifestyle clinicians increasingly encounter patients 10-20 years after their initial revascularization procedure in whom repeat revascularization is not possible or only to a limited extent. Current first line anti-anginal drugs are very effective, but in some patients their use can be precluded due to side effects (especially in pre-existing bradycardia or hypotension).

Over the last decade inorganic nitrate (putatively via the nitrate-nitrite-nitric oxide pathway) has been at the centre of considerable interest as a potential therapeutic option for cardiovascular diseases (2,3). The human body is able to produce endogenous nitrite and nitrate via oxidation of nitric oxide originating from nitric oxide synthases (NOSs). However the major source of the body storage pool comes from diet. Beetroot and leafy green vegetables are especially rich in inorganic nitrate. Inorganic nitrate is actively transported into the salivary glands and secreted into the saliva. Salivary bacteria reduce the nitrate into nitrite. This is in turn reduced to nitric oxide in the stomach, an effect which is facilitated by the presence of low pH. The nitric oxide and some of the remaining nitrite is absorbed in the upper small intestine and reaches all tissues via circulation presumably via conversion back to nitrite which is more stable. Intravenous nitrite (the main metabolite of inorganic nitrate) is a potent vasodilator under hypoxia, but only a modest vasodilator under normoxia (4,5). Nitrite reduces the increase in pulmonary arterial pressure induced by hypoxia in healthy volunteers, an effect which persisted even one hour after cessation of nitrite infusion when plasma levels returned back to the baseline (5). A single dose of oral sodium nitrate elevated angiogenic markers and recruited circulating angiogenic cells in healthy human volunteers (6). Improved angiogenesis was confirmed in an experimental animal model of chronic hind limb ischaemia following chronic oral supplementation (7). Recently four week supplementation with sodium nitrate resulted in improved endothelial dysfunction when assessed by brachial artery flow mediated vasodilation and also reduce arterial stiffness in an elderly population(8). A recent meta-analysis suggests that a dose of 300 to 600mg of sodium nitrate modestly reduces blood pressure (9). Oral inorganic nitrate supplementation was shown to reduce the oxygen cost of submaximal exercise in healthy volunteers (10-12), to improve skeletal muscle contractile function (11,13) and skeletal muscle mitochondrial ATP production efficiency (14). Recently improved skeletal muscle contractile function was documented following a single dose of oral inorganic nitrate load (11.2 mmol beetroot juice) in patients suffering with systolic heart failure (15). It is unclear whether these effects in skeletal muscle also occur in cardiac muscle. However these vascular and myocyte properties would potentially be of therapeutic value in patients suffering from angina.

Hypothesis

The main hypothesis is to assess the effects of oral sodium nitrate treatment in patients with stable angina treated with background cardiovascular and anti-anginal medication.
Primary outcome:

- Time to 1mm ST depression (exercise treadmill test)

Secondary outcomes:

- Time to chest pain onset (exercise treadmill test)
- Total exercise time (exercise treadmill test)
- Angina and GTN use frequency
- Modified Seattle Questionnaire
- Nitrate and nitrite plasma levels, angiogenic markers
- Dobutamine Stress Echocardiography - Tissue Doppler Imaging
  - Myocardial contractility assessment by peak systolic velocity

Methods

Design

The trial has a randomised, placebo controlled, double-blind, crossover design. The study is approved by the Scotland A Research Ethics Committee (SAREC), subject to MHRA regulation, and ran in accordance with the Declaration of Helsinki. All patients will sign an informed written consent.

Patient selection and protocol

Patients aged 18 and over with chronic exertional angina (≥2 months duration) will be interviewed, examined and asked to give a written informed consent. Entry criteria will be positive ECG treadmill test (ETT) and either angiographic evidence of obstructive coronary artery disease or if not available a positive dobutamine stress echocardiogram or a positive myocardial perfusion scan. Patients will be screened with two modified-Bruce protocol ETTs on separate days and enrolled only if they have replicable exercise induced ECG evidence of ischaemia (≤15% difference in time to 1mm ST segment depression at the J+80ms point between the first and the second baseline ETT (16), Figure 1.

Exclusion criteria will be inability to perform an exercise treadmill test, women of child bearing potential, G6PD deficiency, LV ejection fraction <45% or New York Heart Association heart failure class III or IV, myocardial infarction or revascularisation within the last two months, resting ST depression ≥ 1mm or LBBB. Additionally patients in non-sinus rhythm and significant valvular disease will not included in the study as these may render the data interpretation unreliable.

Patients will be able to continue their regular anti-anginal medication at a fixed dose apart from long-acting organic nitrates which will be stopped in all patients at least 72 hours prior enrollment. Patients undergoing a concomitant dobutamin stress echocardiogram will be asked to omit their beta-blocker for 48 hours prior their visits in order to facilitate the dobutamine response, unless clinically contraindicated in which case the beta-blocker treatment may continue uninterrupted. This decision will be at the discretion of the researcher (mainly depending on the severity of symptoms) and the elected strategy will be kept fixed throughout all subsequent patient’s visits. Patients will be
allowed to continue short-acting sublingual GTN use and other background angina medication at a fixed dose.

**Figure 1**
Flowchart: randomised double-blind placebo controlled crossover design

![Flowchart](image)

Patient will be excluded if DSE or MPI positive but recent angiographic evidence of non-obstructive coronary artery disease

**Treatment and randomization process**

The trial medication will be manufactured and placed into packs containing two bottles labelled 1 (first treatment visit) and 2 (second treatment visit) at the Western Glasgow Infirmary Pharmacy. Each bottle will include 14 capsules and contains either 600mg (7mmol) of sodium nitrate or placebo (lactose monohydrate) filled in opaque matching hard gelatin capsules. The sequence of treatment randomization to bottle 1 and 2 will be decided according to a list provided by Aberdeen Randomisation Service (CHaRT, University of Aberdeen). At no point during the study will the research team or the patient know which bottle contains which treatment. Following treatment enrollment the patient will be handed out the first bottle and start treatment with one capsule a day for a period of 7-10 days before undergoing a treadmill test and/or DSE and/or blood tests and a second bottle will be handed out. After a two weeks wash out period the second bottle will be started for 7-10 days and same tests performed on the last day. After each arm the patient will returned the bottle with the remaining capsules for compliance assessment and returned to pharmacy. The two weeks wash out period should be sufficient to avoid any confounding carry-over effects of nitrate treatment as its plasma half-life ranges from 5-8h.
Following verbal instruction, patients will be handed-out a written diet advice sheet and asked to follow a low nitrate and nitrite diet, to limit caffeine intake and avoid use of anti-bacterial mouthwash during the treatment weeks. The latter is in order to prevent the loss of nitrate to nitrite bacterial bioconversion which occurs in the oral cavity and forms an integral part of the nitrate/nitrite entero-salivary circulation (17). On the morning of the test the patients will be asked to avoid any caffeine intake and take the last study capsule approximately two hours prior their visit.

**Exercise Treadmill Test**

Seventy patients will undergo an ECG treadmill test following each treatment arm. They will be performed approximately two hours following ingestion of the last study capsule to ensure the nitrate to nitrite bioconversion can take place. Automated blood pressure monitoring and 12 lead ECGs will be recorded at rest in standing position and during a modified Bruce protocol (at the end of each stage, at the time of first 1mm ST depression, at time of first chest pain onset, at peak exercise and every three minutes into recovery). In patients with minor resting ST depression (<1mm), the time to 1mm ST change will be defined as additional ST depression of 1mm below the resting value as digitally displayed at J point + 80 ms(18).

**Dobutamine Stress Echocardiography**

All patients with a positive ECG treadmill test will be invited for a screening contrast dobutamine stress echocardiogram (DSE). Only patients with evidence of inducible regional wall motion abnormalities, satisfactory echo windows, tolerating well the baseline scan will be enrolled into the DSE arm. All tests will run two hours following finish of the ETT and approximately five hours following the last capsule ingestion (to allow optimal treatment plasma levels).

A standard protocol will involve resting for 20 minutes, baseline acquisition, loading with dobutamine 10ug/kg/min for 5 minutes and then 20, 30 and 40ug/kg/min each for 3 minutes. The pre-defined endpoints will be: inducible regional wall motion abnormality, significant chest pain, ST depression >2mm or ST elevation, persistent arrhythmia and symptomatic BP fall. In patients with poor heart rate rise without any other predefined end-points atropine (up to total of 1.2mg) can be added from 30mcg/kg/min stage onwards to reach at least 85% of age predicted target HR (0.85*220-age)(19). LV contrast agent will be used as this was previously shown to significantly improve detection of inducible regional wall motion abnormalities (20). Six views (apical 4-chamber, 2-chamber, 3-chamber, parasternal short axis at base, mid ventricle and apex) will be routinely obtained.

Patients with an evidence of inducible regional wall motion abnormality on screening will be enrolled into the DSE arm and undergo two further tests, one following each treatment arm. These on-treatment DSEs will run using exactly the same individual pharmacological protocol (dobutamine stage ± fixed atropine dose) as defined during the patient’s screening exam. Images will be obtained without contrast using Doppler tissue velocity imaging (TVI, Q-stress) in apical 4-chamber, 2-chamber and 3-chamber view only. Image depth, width, color tissue doppler velocity scale and frame rate will be optimized to avoid aliasing and aim at >120 frames/s. During passively held end-expiration three loops will be recorded in each view in the last minute of each stage. Digitized
images will be later analyzed off line. Longitudinal basal segment peak systolic velocity (Sp) is the most reproducible tissue Doppler parameter, sensitive to ischaemia and related to blood flow (21,22). Sp will be measured in 6 segments: basal inferoseptum, basal lateral, basal inferior, basal anterior, basal posterior and basal anteroseptum as previously described (23). Sp will be measured as the maximal velocity following isovolumic contraction averaged from three cycles.

**Bloods**

Twenty patients will be invited additionally to take part in the blood subgroup. These patients will have blood taken on three occasions: their final screening visit and the two on-treatment visits. All will attend fasting from midnight, but clear water will be allowed with their morning medication. Patients will be advised to take the last study capsule approximately two hours prior to their study visit. Diabetic patients taking either tablet or insulin treatment will not be included in this substudy in order to avoid hypoglycemia when fasting and exercising. Blood will be taken prior to the treadmill test and samples for Angiogenic markers- sFlt-1, PlGF and VEGF in Li-Heparin tubes and nitrate/nitrite aliquots will be sampled into EDTA tubes which will be supplemented with N-Ethylmaleimide (NEM).

**Nitrite/nitrate plasma levels**

All samples will be spun immediately for 5 minutes at 1000g at room temperature, supernatant will be saved and snap frozen in liquid nitrogen and stored by -80°C. Nitrite/nitrate levels will be analyzed at the University of Southampton (27). Frozen plasma samples will be thawed in the presence of N-ethylmaleimide (10 mM final concentration) and deproteinized by methanol precipitation immediately prior to analysis. Plasma nitrite and nitrate will be measured by high-pressure liquid ion chromatography with post-column derivatization using a dedicated analysis system (ENO-20 with Gilson 234 autoinjector, EPC-500 data processor and PowerChrome software; Eicom).

**Angiogenic markers**

Vascular endothelial growth factor (VEGF) and its receptor (VEGFR-1 = Flt-1) play a central role in maintaining endothelial cell integrity and in the promotion of angiogenesis and lymphogenesis. Soluble Flt-1 (soluble Fms-like tyrosine kinase-1 also known as soluble VEGF receptor-1 or sFlt-1) is derived from the ligand binding region of VEGFR-1/Flt-1 and its main function is believed to be in the regulation of VEGF bioavailability and hence suppression of VEGF signaling(28).

**Modified Seattle Questionnaire, GTN use and angina frequency**

The Seattle Questionnaire (SQ) was developed in the 1990’s as a 19-item quality of life questionnaire assessing five dimensions of patients suffering from angina: physical limitation, angina stability, angina frequency, treatment satisfaction and disease perception (37). It is widely used and was validated as a functional instrument in cardiovascular research outcome (38-42). We modified the questionnaire to reflect the short treatment period of one week in our study when compared to the original SQ which in contrast interrogates over a period of the last four weeks. The higher the score the better is the quality of life, angina control and disease perception. Patients will be handed out a
checklist where they will document the frequency of their angina attacks and GTN use during their

treatment weeks.

**Statistical analysis**

Based on data from several previous randomized controlled studies testing the efficacy of anti-
anginal medication with ECG exercise treadmill tests, the mean improvement in time to 1 mm ST
depression between the active and placebo groups was around 50 sec [36sec with amlodipine
(29,30), 60 sec with organic nitrates (31), 46 sec with atenolol and ranolazine (32), 46 sec with
ivabradine(33) or 43 sec with allopurinol (16)]. The standard deviation in cross-over studies ranged
around 80-90 sec (29,31,34,35). Projecting an expected absolute mean treatment difference
between the two arms of 30 s and a SD of 80 sec and allowing for a significance of 0.05 at 80%
power in a paired crossover trial design, would require a sample size of 58 patients. To allow for
drop-outs we planned to randomize 70 patients.

For the secondary dobutamine stress echocardiogram endpoint of tissue Doppler velocity derived
peak systolic velocity (Sp) we aim to invite all eligible patients, but we recognize that many patients
may not participate either due to contraindications, not tolerating the baseline scan or frequently
their personal choice to opt out of this subgroup as the research visits will last significantly longer
and often may interfere with their social or working life. We will aim to recruit a minimum of twenty
patients based on a previous study by Ingram et al who showed that single intravenous nitrite
infusion (30µmol NaNO2) increased peak systolic velocity in ischaemic segments when compared to
saline infusion (N=10, 9.5±0.5 vs 12.4±0.6cm/s, p<0.001) (Ingram, JACC 2013). A sample size of 16
patients would be necessary to observe 1.0 cm/s velocity difference Sp and a standard deviation of
1.0 cm/s (two-tailed, paired, power 0.95 and p=0.05).

The primary endpoint (time to 1mm ST-Depression) is assumed to follow a Normal distribution. The
analysis will follow that recommended by Senn(36) for the analysis of a 2-treatment, 2-period cross-
over trial. A General Linear Model (GLM) will be constructed with the following terms included:
participant (as a random effect), period and treatment (both as fixed effects). Baseline terms will
not be included as baseline data is not available for both treatment periods. Baseline data will,
however, be tabulated and described, by randomised group (i.e. by treatment sequence). Treatment
efficacy will be estimated as the treatment effect estimate from the GLM with a 95% confidence
interval constructed and the hypothesis of zero effect tested (at the 5% significance level).

Secondary endpoints will be analysed in the same manner. For some endpoints (for example
number of angina attack episodes), the assumption of a Normal distribution is unlikely to hold and
an appropriate transformation will be carried out prior to analysis (for example a logarithmic or
square-root transformation). The residuals from each model will be check to follow and
approximate Normal distribution. The trial statistician will conduct and report the analyses blind, i.e.
simply comparing treatment ‘A’ to treatment ‘B’ according to the randomisation schedule provided,
without knowing which treatment is active or placebo. All analyses will be carried out in SAS version
9.3.
**Trial Oversight**

A Trial Steering Committee will oversee, monitored and supervised the progress of the study and will be responsible for the scientific integrity of the research. Data Monitoring Committee will monitor the safety of the study and research validity of its conduct. Research and Development department of the University of Aberdeen will act as the sponsor and monitor of the study. The study is registered and underwent regulatory approvals by the MHRA (Medicine and Healthcare Regulatory Agency), NHS-Grampian R&D department and the Research Ethics Committee.

**Conclusion**

In the aging population increasing proportion of patients with advanced coronary disease survive to the stage when no more revascularization is possible and first line antianginal treatment options are exhausted. Inorganic nitrate treatment offers via nitrate-nitrite-nitric oxide treatment pathway a unique anti-anginal strategy by theoretical improving selective vasodilation in hypoxic territories, promotion of vasodilation or improved mitochondrial efficiency. While sound in experimental animal studies and pilot studies on healthy volunteers, this study proposes to investigate potential anti-anginal benefits of sodium nitrate in elderly population of patients suffering with angina and known advanced atherosclerotic disease who are on background poly-pharmacy.

**Funding**

The study is funded by the Medical Research Council.

Edura CT number: 2012-000196-17

Trial Registration: ClinicalTrials.gov  NCT02078921

**Acknowledgement**

We are very grateful to Amanda Cardy (Scottish Primary Research Network) for her help with recruitment from primary care centres. Further thanks are to Val Harries, Amelia Rudd and Frances Adamson for their assistance with facilitation of study recruitment.


